Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,466 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01105650 | Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | completed | Phase 2 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00003532 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer | terminated | Phase 2 | 7 | Burzynski Research InstituteOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT01617629 | Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study(CAN-003X) | completed | Phase 2 | 9 | Prima BioMed LtdINDUSTRY | 2 | Dec 8, 2017 | clinicaltrials |
| NCT00888173 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00334893 | Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00470366 | Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors | completed | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00068406 | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva | completed | Phase 2 | 61 | Gynecologic Oncology GroupNETWORK | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00562185 | Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00941070 | Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03335241 | Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer | unknown | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00937560 | A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 9 | Nov 6, 2017 | clinicaltrials |
| NCT02432365 | Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy | unknown | Phase 2 | 64 | Chang Gung Memorial HospitalOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT03032614 | Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Oct 10, 2017 | clinicaltrials |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Oct 9, 2017 | clinicaltrials |
| NCT02278783 | Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer | terminated | Phase 2 | 1 | University of UtahOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00003525 | Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva | terminated | Phase 2 | 8 | Burzynski Research InstituteOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT03298074 | Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 60 | Yang ZhijunOTHER | 0 | Sep 29, 2017 | clinicaltrials |
| NCT00081263 | Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia | completed | Phase 2 | 130 | Gynecologic Oncology GroupNETWORK | 1 | Sep 15, 2017 | clinicaltrials |
| NCT00857545 | OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission | completed | Phase 2 | 171 | Gynecologic Oncology GroupNETWORK | 1 | Sep 13, 2017 | clinicaltrials |
| NCT01039207 | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Sep 7, 2017 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT00354601 | Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT00039442 | Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 21 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00600210 | Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer | withdrawn | Phase 2 | 0 | Leo W. Jenkins Cancer CenterOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01991210 | A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) | terminated | Phase 2 | 95 | Genentech, Inc.INDUSTRY | 7 | Aug 21, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00004221 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | terminated | Phase 2 | 12 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT00408603 | Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer | completed | Phase 2 | 183 | Sunesis PharmaceuticalsINDUSTRY | 2 | Jul 27, 2017 | clinicaltrials |
| NCT00856791 | Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients | completed | Phase 2 | 1 | Traws Pharma, Inc.INDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01905163 | Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients(CILOVE) | completed | Phase 2 | 47 | Centre Jean PerrinOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00003865 | Toremifene in Treating Patients With Ovarian Cancer | withdrawn | Phase 2 | 0 | George Washington UniversityOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00045682 | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 78 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00054119 | Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01754519 | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery | terminated | Phase 2 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT00332033 | Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids) | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00511992 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | completed | Phase 2 | 20 | University of OklahomaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02684318 | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Poveda, Andrés, M.D.INDIV | 1 | Jun 22, 2017 | clinicaltrials |
| NCT01184053 | Trisenox® in Women With Metastatic Endometrial Cancer(NRR) | terminated | Phase 2 | 3 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00061308 | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer | completed | Phase 2 | 75 | GlaxoSmithKlineINDUSTRY | 2 | Jun 9, 2017 | clinicaltrials |
| NCT00739661 | A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission | completed | Phase 2 | 104 | Genentech, Inc.INDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT01972516 | Tivozanib As Maintenance Therapy In GYN | terminated | Phase 2 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01461746 | Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer | unknown | Phase 2 | 67 | Asan Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01462149 | Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer | completed | Phase 2 | 43 | Asan Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00376987 | Zinc Supplements in Lowering Cadmium Levels in Smokers | completed | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00534001 | Bupropion in Helping Adults Stop Smoking | completed | Phase 2 | 95 | Roswell Park Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01681368 | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 30, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Dec 28, 2017source: clinicaltrials